What Shows Up as Benzodiazepines on a Drug Test?

Standard urine drug screens look for benzodiazepines by targeting a handful of common metabolites, which means the list of substances that trigger a positive result is both narrower and wider than most people expect. Several prescribed benzodiazepines routinely slip past the test entirely, while certain unrelated medications can light it up. The mismatch between what the test is supposed to catch and what it actually catches creates real confusion for patients, clinicians, and anyone subject to workplace or legal drug testing.

How Screening Tests Decide You Have Benzodiazepines

Most initial drug screens use a technology called immunoassay. Rather than identifying each individual drug by name, the test relies on antibodies designed to latch onto specific chemical shapes. For benzodiazepines, the antibodies in widely used screening kits are calibrated to recognize nordiazepam and oxazepam, which happen to be the downstream metabolites of many classic benzodiazepines like diazepam (Valium) and chlordiazepoxide (Librium).¹ If a substance in the urine looks enough like those target metabolites to the antibody, the test reads positive. If it doesn’t resemble them closely enough, the test reads negative, even if the person took a benzodiazepine hours ago.

This is the core issue. The test does not scan for “all benzodiazepines.” It scans for a particular chemical fingerprint shared by some benzodiazepines. Everything that follows, the false negatives and the false positives, stems from this design choice.

Benzodiazepines the Test Reliably Catches

The benzodiazepines most likely to produce a positive result are those whose metabolic breakdown funnels through nordiazepam or oxazepam. Diazepam is the classic example: your body converts it to nordiazepam, then to oxazepam, both of which the antibodies recognize well. Clorazepate and chlordiazepoxide follow similar routes and are generally detected without trouble.

Beyond these, other benzodiazepines that produce metabolites structurally close to the antibody targets tend to show up reliably at standard doses. Temazepam, for instance, is itself converted to oxazepam and usually triggers a positive screen. The key pattern is straightforward: if the drug eventually becomes oxazepam or nordiazepam in your body, the standard test is likely to flag it.

Benzodiazepines the Test Often Misses

Here is where things get counterintuitive. Several of the most commonly prescribed benzodiazepines follow metabolic pathways that do not produce nordiazepam or oxazepam, and as a result, the standard immunoassay frequently returns a negative result even when the person is actively taking them. The drugs with the worst track record for detection include alprazolam (Xanax), clonazepam (Klonopin), lorazepam (Ativan), and triazolam (Halcion).¹

This is not a rare edge case. Alprazolam and clonazepam are among the most widely prescribed benzodiazepines, and lorazepam is a hospital staple. One study evaluating two immunoassay techniques found that neither reliably detected therapeutic doses of lorazepam, and one of them also missed chlordiazepoxide, nitrazepam, flunitrazepam, and triazolam.² The researchers concluded that both techniques, when used as their manufacturers intended, were unreliable for detecting therapeutic doses of several studied benzodiazepines.

One lab study found that by lowering the absorbance cutoff used to flag a sample for confirmatory testing, the false-negative rate for benzodiazepines dropped dramatically, from roughly half of confirmed users to about two percent.³ That gives a sense of how many positives the standard settings miss. But most testing facilities use the manufacturer’s default cutoff, so in practice, these drugs are routinely undetected.

Why Glucuronide Hydrolysis Matters

Part of the detection problem is biological. Your body doesn’t just metabolize benzodiazepines into other compounds; it also attaches sugar molecules (glucuronide groups) to those metabolites before excreting them in urine. This chemical tagging changes the shape of the metabolite enough that the immunoassay antibody barely recognizes it. One study found that without a hydrolysis step to strip off those sugar tags, glucuronidated forms of temazepam, oxazepam, and lorazepam showed less than one percent cross-reactivity in the assay.⁴ After enzymatic hydrolysis, cross-reactivity climbed significantly. Only trace amounts of the parent benzodiazepines are present in urine without this step, because so much of what gets excreted is in conjugated form.⁵

Some labs include an enzymatic hydrolysis step in their workflow, and some don’t. If yours doesn’t, the odds of catching lorazepam or temazepam on a standard screen drop substantially. This is a behind-the-scenes processing detail that most people being tested never learn about, and it can make the difference between a positive and a negative result.

Non-Benzodiazepine Drugs That Trigger False Positives

Because immunoassays work by shape recognition rather than precise chemical identification, several medications that have nothing to do with benzodiazepines can fool the test. The best-documented culprits include:

Oxaprozin (Daypro): This anti-inflammatory drug, used for arthritis, is the most reliably cross-reactive non-benzodiazepine. In a study of 12 subjects taking oxaprozin, all 36 urine samples tested positive on two widely used immunoassays, and 35 of 36 tested positive on a third.⁶ It is not a benzodiazepine. It is an NSAID in the same general family as ibuprofen.⁷
Efavirenz (Sustiva): This HIV medication caused positive benzodiazepine screens in 49 out of 50 patients taking it, compared to just 1 out of 50 not on the drug. The cross-reactivity comes from its major metabolite, 8-hydroxy-efavirenz, which apparently mimics the shape the antibody is looking for.⁸
Sertraline (Zoloft): The antidepressant sertraline has been associated with false-positive benzodiazepine screens. A retrospective review of over 500 records found that among false-positive results not explained by a benzodiazepine prescription, sertraline was the most common co-prescribed medication.⁹

These aren’t exotic scenarios. Oxaprozin is a common arthritis medication. Sertraline is one of the most prescribed antidepressants in the world. If you take any of these and face a benzodiazepine screen, a false positive is a real possibility, and you should mention your medication list to whoever orders the test before the results come back.

What About Z-Drugs Like Ambien?

The “Z-drugs,” non-benzodiazepine sleep medications like zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta), act on the same brain receptors as benzodiazepines but have a different chemical structure. The question of whether they trigger a positive screen has a frustratingly inconsistent answer.

An older study using two standard immunoassay platforms found that zolpidem produced no positive results at any time point up to 24 hours after dosing.¹⁰ That study specifically tested the EMIT and ADx assay kits. However, a later study using ELISA-based kits told a different story: nearly all samples screened positive for benzodiazepines, even when confirmatory testing by mass spectrometry found no zolpidem present in the urine.¹¹

The takeaway is that whether zolpidem shows up depends heavily on which test kit a lab uses. Some assay platforms ignore it completely. Others react to it as though it were a benzodiazepine. You cannot predict the result without knowing which specific kit your testing facility runs, and most people being tested don’t have that information.

Designer Benzodiazepines and Detection Gaps

A growing concern involves “designer benzodiazepines,” novel compounds synthesized to mimic the effects of traditional benzodiazepines while evading drug scheduling and detection. Substances like etizolam, clonazolam, flualprazolam, and flubromazolam have appeared in illicit markets and are increasingly involved in overdose cases.¹²

Standard immunoassays were never designed to detect these compounds. Their metabolic pathways are poorly characterized, and their metabolites may have little structural overlap with the nordiazepam and oxazepam targets the tests look for. Some designer benzodiazepines happen to cross-react weakly with screening assays and might trigger a positive at high doses, but many would be completely invisible to a routine test. Detection generally requires advanced mass spectrometry techniques that are not part of standard workplace or clinical screening panels.

This gap has practical implications. Someone using a potent designer benzodiazepine could pass a routine drug screen while being profoundly impaired. Emergency departments faced with a sedated patient and a clean drug screen may not consider designer benzodiazepines unless they specifically order expanded testing panels.

How Confirmatory Testing Changes the Picture

When an immunoassay result matters enough to act on, whether in a clinical setting, a workplace, or a courtroom, confirmatory testing using a mass spectrometry method is the standard next step. Rather than relying on shape-recognition by antibodies, mass spectrometry identifies molecules by their exact molecular weight and fragmentation pattern. It can distinguish diazepam from oxaprozin, confirm the specific benzodiazepine present, and rule out cross-reactive interferences.

Confirmatory testing also catches what the screen misses. In one study that ran mass spectrometry on samples initially flagged negative by immunoassay, about a third of those “negative” samples turned out to contain a benzodiazepine.¹³ Conversely, about eleven percent of the immunoassay-positive samples were not confirmed, presumably representing false positives from cross-reactive substances.

The practical limitation is that confirmatory testing costs more, takes longer, and is not always ordered. In many clinical settings, the immunoassay result is treated as the final word unless someone specifically requests confirmation. If you believe a result is wrong, asking for confirmatory mass spectrometry testing is the most direct way to settle it.

Detection Windows and Factors That Extend Them

The window during which a benzodiazepine appears in urine depends on the specific drug, the dose, how long the person has been taking it, and individual factors like liver function, age, and body composition. Short-acting benzodiazepines taken as a single dose may be undetectable within a day or two. Long-acting ones like diazepam can leave detectable metabolites for weeks after the last dose, because nordiazepam itself has a long half-life and accumulates in fatty tissue.

Lorazepam, for instance, was detectable in urine for over 144 hours (about six days) after a single dose using sensitive mass spectrometry, though the window was much shorter in oral fluid, only about eight hours.¹⁴ Remember, though, that lorazepam is one of the drugs the standard immunoassay often misses, so a long detection window by mass spectrometry doesn’t mean the screening test would catch it during that entire period.

Alcohol dependence introduces another wrinkle. Research on patients undergoing alcohol withdrawal treatment found that active benzodiazepine metabolites were still present in urine during the third and fourth weeks after benzodiazepines were stopped, at levels comparable to those seen during active therapeutic dosing.¹⁵ In people with a history of heavy drinking, impaired liver metabolism and redistribution from body fat can keep metabolites circulating far longer than textbook half-lives would predict. Clinicians monitoring sobriety in this population should be aware that a positive benzodiazepine screen does not necessarily indicate recent use.

Specimen Tampering and Adulterants

In contexts like workplace testing or criminal justice monitoring, the possibility that someone has tampered with their urine sample is a real consideration. Research has shown that several common household products can suppress immunoassay drug signals when added to urine. In one study, bleach, drain cleaner, vinegar, and sodium nitrite all generated false-negative results for multiple drug classes at concentrations as low as about five percent of the sample volume.¹⁶

Different assay platforms have different vulnerabilities. A study testing the CEDIA assay platform found strong interference from glutaraldehyde, detergent, and high concentrations of bleach and drain cleaner, but minimal interference from baking soda, table salt, and vinegar.¹⁷ The inconsistency between the two studies on vinegar’s effects illustrates how much the specific assay technology matters.

Modern testing facilities typically check for adulterants by measuring urine pH, specific gravity, temperature, and oxidant levels. Abnormal values prompt rejection of the sample or repeat collection under observation. But the arms race between testing and tampering is ongoing, and no set of validity checks catches every adulterant at every concentration.

Oral Fluid and Hair as Alternatives to Urine

Urine is the standard specimen for drug testing, but it is not the only option, and alternative specimen types have different strengths and weaknesses for benzodiazepine detection. Oral fluid (saliva) testing avoids the privacy issues of observed urine collection and is harder to tamper with, but its detection window for benzodiazepines tends to be much shorter. In the lorazepam study mentioned earlier, oral fluid tested positive for only about eight hours compared to six days in urine.¹⁴

Hair testing offers a much longer retrospective window, potentially months, but has its own blind spots. The same study found that a single dose of lorazepam could not be detected in hair at all, even with a very low quantitation threshold. Most other benzodiazepines do incorporate into hair, making lorazepam something of an outlier. For investigations involving suspected drug-facilitated crimes, where lorazepam is sometimes involved, urine collected promptly remains the most reliable specimen type.

What to Do If You Think a Result Is Wrong

If you take a prescribed medication that you suspect caused a false positive, or if you take a benzodiazepine that you believe the test missed, request confirmatory testing by mass spectrometry. This is the single most useful step you can take. The immunoassay screen is a blunt tool by design: it is meant to be fast, cheap, and broadly sensitive. It is not meant to be the last word.

Bring your full medication list to whoever oversees the test. Oxaprozin, sertraline, efavirenz, and certain other medications have documented cross-reactivity, and a medical review officer (the physician who interprets workplace drug test results) can take prescriptions into account when evaluating a positive screen. For benzodiazepines that the screen is known to miss, like alprazolam or clonazepam, the only way to document their presence is through a targeted confirmatory panel. If compliance monitoring matters, as it does in pain management contracts or substance abuse treatment, the clinician ordering the test should specifically request an expanded benzodiazepine confirmation panel rather than relying on the standard screen alone.